AOUConsorziale Policlinico Di Bari
Bari, 70124, Italy
NCT Number: NCT04223206
The objective of the pilot study is to validate the clinical use of a dietary supplement for contrasting sarcopenia in dialysis patients.
The study aims at evaluating the effects of a nutritional supplement, consisting of flour from Lens culinaris of Altamura IGP, pea proteins and vitamins (A, B12, D, E) by achieving the following objectives:
* Reduction of sarcopenia conditions, through improvement of nutritional and anthropometrical levels * Decrease of the serum levels of microbiota-derived uremic toxins * Reduction of intestinal permeability and inflammatory markers
Looking for future studies?
Notify Me60 year and older
All sexes
Interventional
Not applicable
Bari, 70124, Italy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral administration of dietary supplement (26 g/day) to dissolve in 100 or 150 mL of water
Time frame: 3 months
Change of muscle mass by bioelectrical impedance assessment (BIA)
Time frame: 3 months
Change of sarcopenia assessed by the European Working Group on Sarcopenia in Older People (EWGSOP) guidelines through the SARC-F (Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls) questionnaire. The SARC-F scale scores range from 0 to 10 (i.e. 0-2 points for each item; 0=best to 10=worst) and represents no sarcopenia (0-3) and sarcopenia (4-10).
Time frame: 3 months
Measurement of MNA questionnaire (12-14 points, normal nutritional status; 8-11 points, at risk of malnutrition; 0-7, malnourished)
Time frame: 3 months
Measurement of the arm circumference (cm)
Time frame: 3 months
Measurement of BMI (kg/m^2)
Time frame: 3 months
Change of gastrointestinal symptoms assessed by Gastrointestinal Symptom Rating Scale (GSRS) questionnaire (15 items scored 1-7 each, 1 representing the best and 7 the worse outcome for each item).
Time frame: 3 months
Change of stool type evaluated by BRISTOL Stool Scale (range 1-7, lower and higher values representing worse outcome, middle values representing better outcome).
Time frame: 3 months
Change of free and total indoxyl sulfate (IS) and p-cresyl sulfate (pCS) serum concentrations (μg/mL) assessed by liquid chromatography/mass spectrometry
Time frame: 3 months
Change of serum concentrations of interleukins: IL-6, TNF-α, IL-1, IL-8, IL-10 (pg/mL) evaluated by ELISA
Time frame: 3 months
Change of glycemia concentration (mg/dl)
Time frame: 3 months
Change of insulin concentration (pmol/L)
Time frame: 3 months
Change of C-peptide, growth hormone (GH), insulin-like growth factor 1 (IGF-1), testosterone concentration (ng/mL)
Time frame: 3 months
Change of D-lactate serum concentration (uM)
Time frame: 3 months
Change of the relative abundance (%) of Operational Taxonomic Units (OTUs) of Firmicutes, Bacteroidetes,Proteobacteria, Verrucomicrobia, Actinobacteria, Synergistetes, Cyanobacteria, Euryarchaeota, Chloroflexi, Nitrospirae, Tenericutes, Fusobacteria, Thermotogae, Acidobacteria evaluated by fecal bacterial DNA genome sequencing.
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Other
K2DTD75 - ALTIS "Alimento Funzionale a Base di Lens Culinaris Tipico Del Territorio Pugliese ed Innovativo Per la Salute" - Regione Puglia "INNONETWORK 2017"
Acronym: ALTIS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06660160
Atrophy, Behavior
Massamagrell, Valencia, Spain
View Trial DetailsNCT04898608
Atrophy, Chronic Disease
Isfahan, Iran
View Trial DetailsNCT07704008
Anxiety Disorders, Female Urogenital Diseases
Ankara, Turkey (Türkiye)
View Trial DetailsNCT07334522
Agnosia, Anxiety
Karbala, Iraq
View Trial Details